EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer

Kanan Alshammari, Kyaw L Aung, Tong Zhang, Albiruni R A Razak, Stefano Serra, Tracy Stockley, Lisa Wang, Jessica Nguyen, Anna Spreafico, Aaron R Hansen, Dave Zwir, Lillian L Siu und 1 weitere

Clinical Colorectal Cancer · 2021-12 · 20 (4) · 334-341

DOI: 10.1016/j.clcc.2021.07.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Colorectal Cancer, 2021-12. Verfasst von Kanan Alshammari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, Uni…. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, GlaxoSmithKline, Servier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: MEK inhibition may overcome resistance to EGFR inhibition in patients with RAS wildtype (wt) metastatic colorectal cancer (mCRC). We evaluated antitumor activity of trametinib (MEK1/2 inhibitor) with panitumumab (EGFR monoclonal antibody) in a phase II trial. METHODS: Patients with KRAS, NRAS, and BRAF wt mCRC with prior 5-FU, irinotecan, oxaliplatin, +/- bevacizumab and no prior anti-EGFR therapy were treated with trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks. Primary endpoint was clinical benefit rate (CB; CR, PR, or SD ≥24 weeks) by RECIST v1.1. A 2-stage minimax design was used. Serial plasma circulating free DNA (cfDNA) was collected and profiled using Oncomine Lung cfDNA assay. RESULTS: Fourteen patients were enrolled from November 2015 to April 2019. CB rate was 38% (5/13) and median progression free survival (PFS) was 4.4 months (95% CI, 2.9-7.1). Confirmed overall response rate was 38% (5/13). Treatment-related AE (trAE) included acneiform rash (85%), diarrhea (62%), maculopapular rash (54%), mucositis (46%), and others. Dose modifications and interruptions of trametinib occurred in 69% and panitumumab in 54% of patients. The trial did not progress to stage II accrual due to tolerability and short duration of response. RAS or BRAF mutations cfDNA were detected in 3/13 patients (23%) before radiographic disease progression. CONCLUSION: The addition of trametinib to panitumumab led to a high rate of tumor shrinkage in RAS/RAF wt metastatic colorectal cancer, with poor tolerability due to a high incidence of skin toxicity. Median PFS was similar to panitumumab alone in historical control data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansPanitumumabPyridonesPyrimidinones

Stichwörter der Autor:innen

Circulating free DNAEGFRMEKclinical trialcolorectal cancer

Substanzen

PyridonesPyrimidinonestrametinibPanitumumab

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Ontario.
  • Department of Clinical Laboratory Genetics, University Health Network, Toronto, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Biostatistics Division, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Ontario. Electronic address: philippe.bed…

Förderung

  • NCI NIH HHS
  • GlaxoSmithKline
  • Servier
  • Sanofi
  • Pfizer
  • AstraZeneca
  • Genentech
  • Bristol-Myers Squibb Canada

Zitieren

APA

Alshammari, K., Aung, K. L., Zhang, T., Razak, A. R. A., Serra, S., Stockley, T., Wang, L., Nguyen, J., Spreafico, A., Hansen, A. R., Zwir, D., Siu, L. L., & Bedard, P. L. (2021). Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 20(4), 334-341. https://doi.org/10.1016/j.clcc.2021.07.004

Vancouver

Alshammari K, Aung KL, Zhang T, Razak ARA, Serra S, Stockley T, et al. Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 2021;20(4):334-341. doi:10.1016/j.clcc.2021.07.004

BibTeX
@article{Alshammari2021,
  author = {Alshammari, Kanan and Aung, Kyaw L and Zhang, Tong and Razak, Albiruni R A and Serra, Stefano and Stockley, Tracy and Wang, Lisa and Nguyen, Jessica and Spreafico, Anna and Hansen, Aaron R and Zwir, Dave and Siu, Lillian L and Bedard, Philippe L},
  title = {Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer},
  journal = {Clinical Colorectal Cancer},
  year = {2021},
  volume = {20},
  number = {4},
  pages = {334--341},
  doi = {10.1016/j.clcc.2021.07.004}
}
Kostenlos starten →